Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Legal Hurdles | Pacira faces patent challenges and potential generic competition, threatening its market dominance with flagship product Exparel |
Growth Amid Adversity | NOPAIN initiative and new partnerships offer hope for expansion, despite recent revenue miss and market pressures |
Analyst Perspectives | Price targets range from $14 to $37, reflecting mixed outlook on Pacira's ability to navigate current challenges and capitalize on opportunities |
Financial Resilience | Strong gross margins and free cash flow yield demonstrate Pacira's ability to maintain profitability in face of market uncertainties |
Metrics to compare | PCRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPCRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −11.2x | −4.3x | −0.6x | |
PEG Ratio | 0.00 | 0.12 | 0.00 | |
Price/Book | 1.4x | 1.0x | 2.6x | |
Price / LTM Sales | 1.5x | 1.4x | 3.1x | |
Upside (Analyst Target) | −18.4% | 106.9% | 51.5% | |
Fair Value Upside | Unlock | 8.0% | 8.4% | Unlock |